Terms: = Sarcomas AND MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7 AND Treatment
224 results:
1. Temporal trends and regional variability in BRAF and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.
Frost MG; Jensen KJ; Jimenez-Solem E; Qvortrup C; Kuhlmann TP; Andersen JL; Høgdall E; Petersen TS
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23236. PubMed ID: 38656617
[TBL] [Abstract] [Full Text] [Related]
2. Decoding the Versatile Landscape of Autophagic Protein VMP1 in Cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
3. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
4. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth downregulating the Wnt/β-catenin pathway.
Junli C; Fulai Z; Xingyuan S; Xiaoping MA; Peng Z; Chujie Z; Binhao S; Wenchao GU; Yongjun W; Yanping Y
J Tradit Chin Med; 2024 Apr; 44(2):251-259. PubMed ID: 38504531
[TBL] [Abstract] [Full Text] [Related]
5. Duodenal malignant melanoma: Primary and metastatic case series and literature review.
Zhou B; Li X; Liu J; Peng L; Liu X
Medicine (Baltimore); 2024 Feb; 103(6):e37138. PubMed ID: 38335433
[TBL] [Abstract] [Full Text] [Related]
6. A Spontaneous Assembling Lipopeptide Nanoconjugate Transporting the Anthracycline Drug
Sabnis N; Raut S; Nagarajan B; Kapic A; Dossou AS; Lothstein L; Fudala R; Bunnell BA; Lacko AG
Bioconjug Chem; 2024 Feb; 35(2):187-202. PubMed ID: 38318778
[TBL] [Abstract] [Full Text] [Related]
7. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
Cho HJ; Yun KH; Shin SJ; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Ryu HJ; Lee J; Cho I; Go H; Ko J; Jung I; Jeon MK; Rha SY; Kim HS
Nat Commun; 2024 Jan; 15(1):685. PubMed ID: 38263321
[TBL] [Abstract] [Full Text] [Related]
8. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract] [Full Text] [Related]
9. Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.
Serbest Ceylanoglu K; Guneri Beser B; Singalavanija T; Juntipwong S; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):18-29. PubMed ID: 38241616
[TBL] [Abstract] [Full Text] [Related]
10. Repurposing Metabolic Inhibitors in the treatment of Colon Adenocarcinoma Patient-Derived Models.
Lee B; Lee C; Moon HM; Jo SY; Jang SJ; Suh YA
Cells; 2023 Dec; 12(24):. PubMed ID: 38132178
[TBL] [Abstract] [Full Text] [Related]
11. [Research Progress of BRAF Fusion in Non-small Cell Lung Cancer].
Xiao P; Zhong D
Zhongguo Fei Ai Za Zhi; 2023 Oct; 26(10):782-788. PubMed ID: 37989341
[TBL] [Abstract] [Full Text] [Related]
12. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
[TBL] [Abstract] [Full Text] [Related]
13. Immune microenvironment of intimal sarcomas: Adaptive immune resistance with potential therapeutic implications.
Birkness-Gartman JE; Thomas DL; Engle LL; Voltaggio L; Thompson ED
Am J Clin Pathol; 2024 Mar; 161(3):256-263. PubMed ID: 37921094
[TBL] [Abstract] [Full Text] [Related]
14. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors.
Stadler JC; Keller L; Mess C; Bauer AT; Koett J; Geidel G; Heidrich I; Vidal-Y-Sy S; Andreas A; Stramaglia C; Sementsov M; Haberstroh W; Deitert B; Hoehne IL; Reschke R; Haalck T; Pantel K; Gebhardt C; Schneider SW
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258039
[TBL] [Abstract] [Full Text] [Related]
16. Neoadjuvant Immune Checkpoint Inhibition in Metastatic Conjunctival Melanoma.
Fan K; Waninger JJ; Yentz S; McLean S; Demirci H
Ophthalmic Plast Reconstr Surg; 2023 Sep-Oct 01; 39(5):e152-e155. PubMed ID: 37207285
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.
Wang A; Liu J; Li X; Zou F; Qi Z; Qi S; Liu Q; Wang Z; Cao J; Jiang Z; Wang B; Ge J; Wang L; Wang W; Liu J; Liu Q
Eur J Pharmacol; 2023 Aug; 952():175752. PubMed ID: 37164118
[TBL] [Abstract] [Full Text] [Related]
18. Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer.
Lin R; Li Y; Lin Y; Tian W; Jiang L; Li J
Diagn Cytopathol; 2023 Jul; 51(7):397-405. PubMed ID: 37078537
[TBL] [Abstract] [Full Text] [Related]
19. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract] [Full Text] [Related]
20. RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells.
Patel H; Mishra R; Wier A; Mokhtarpour N; Merino EJ; Garrett JT
Anticancer Drugs; 2023 Apr; 34(4):519-531. PubMed ID: 36847042
[TBL] [Abstract] [Full Text] [Related]
[Next]